Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sawai Pharmaceutical Co. Ltd.

www.sawai.co.jp

Latest From Sawai Pharmaceutical Co. Ltd.

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

Market Intelligence Generic Drugs

One-Offs Lift Dr Reddy’s In Q2

One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.

Strategy Sales & Earnings

One-offs Lift Dr Reddy’s In Q2, Eyes Gx Suboxone Opportunities

One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.

Commercial Sales & Earnings

Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands

Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.

Value-Added Medicines Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • SAWAI PHARMACEUTICALS LTD.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sawai Pharmaceutical Co. Ltd.
  • Senior Management
  • Mitsuo Sawai, Pres.
  • Contact Info
  • Sawai Pharmaceutical Co. Ltd.
    Phone: (81) 6 6105 5729
    5-2-30, Miyahara
    Yodogawa-Ku
    Osaka, 532-0003
    Japan
UsernamePublicRestriction

Register